1: Hunt HJ, Belanoff JK, Walters I, Gourdet B, Thomas J, Barton N, Unitt J,
Phillips T, Swift D, Eaton E. Identification of the Clinical Candidate
(R)-(1-(4-Fluorophenyl)-6-((1-methyl-1H-pyrazol-4-yl)sulfonyl)-4,4a,5,6,7,8-hexah
ydro-1H-pyrazolo[3,4-g]isoquinolin-4a-yl)(4-(trifluoromethyl)pyridin-2-yl)methano
ne (CORT125134): A Selective Glucocorticoid Receptor (GR) Antagonist. J Med Chem.
2017 Apr 17. doi: 10.1021/acs.jmedchem.7b00162. [Epub ahead of print] PubMed
PMID: 28368581.
2: Bali U, Phillips T, Hunt H, Unitt J. FKBP5 mRNA Expression Is a Biomarker for
GR Antagonism. J Clin Endocrinol Metab. 2016 Nov;101(11):4305-4312. Epub 2016 Jul
26. PubMed PMID: 27459525.
3: Stringer-Reasor EM, Baker GM, Skor MN, Kocherginsky M, Lengyel E, Fleming GF,
Conzen SD. Glucocorticoid receptor activation inhibits chemotherapy-induced cell
death in high-grade serous ovarian carcinoma. Gynecol Oncol. 2015
Sep;138(3):656-62. doi: 10.1016/j.ygyno.2015.06.033. Epub 2015 Jun 24. PubMed
PMID: 26115975; PubMed Central PMCID: PMC4556542.
